Standard methods for producing high-capacity adenoviral vectors (HC-Ads) are based on co-infection with a helper adenovirus (HV). To avoid HV encapsidation, its packaging signal (C) is flanked by recognition sequences for recombinases expressed in the producing cells. However, accumulation of HV and low yield of HC-Ad are frequently observed, due in part to insufficient recombinase expression. We describe here a novel HV (AdTetCre) in which C is flanked by loxP sites that can be excised by a chimeric MerCreMer recombinase encoded in the same viral genome. Efficient modulation of cleavage was obtained by simultaneous control of MerCreMer expression using a tet-on inducible system, and translocation to the nucleus by 4-hydroxytamoxifen (TAM). Encapsidation of AdTetCre was strongly inhibited by TAM plus doxycicline. Using AdTetCre and 293Cre4 cells for the production of HC-Ads, we found that cellular and virus-encoded recombinases cooperate to minimize HV contamination. The method was highly reproducible and allowed the routine production of different HC-Ads in a medium-scale laboratory setting in adherent cells, with titers 410 10 infectious units and o0.1% HV contamination. The residual HVs lacked C and were highly attenuated. We conclude that self-inactivating HVs based on virally encoded recombinases are promising tools for the production of
INTRODUCTION
High-capacity adenoviral vectors (HC-Ads), also called helper-dependent or 'gutless' are promising tools for gene therapy approaches requiring high transduction efficiency, maintenance of gene expression for long periods of time or transfer of large DNA fragments. 1 HC-Ad particles consist of viral capsids from adenovirus (usually human adenovirus type 5) containing a double-stranded linear DNA of up to 36 kb in which only the inverted terminal repeats and the packaging signal (C) are of viral origin. 2 These vectors retain the high infectivity and liver tropism of adenovirus (with all the potential targeting strategies being fully applicable), and eliminate the problems associated with residual viral gene expression. Long-term expression of therapeutic genes using HC-Ads has been demonstrated in different animal models, including non-human primates. 3 The high cloning capacity allows the transfer of large complementary DNAs, extended portions of regulatory regions, or the simultaneous delivery of different transgenes. Therefore, potential medical applications of HC-Ads include metabolic diseases, hemophilia, muscular dystrophy, neurodegenerative disorders and cancer, among others. 3 However, difficulties in large-scale production of clinical-grade HC-Ads limit the use of these vectors in patients. Previous versions of adenoviral vectors, in which only some early genes were deleted, were produced using packaging cell lines with constitutive expression of these genes. 4 In the case of HC-Ad, both early and late viral functions, including expression of structural proteins, should be complemented in a synchronized fashion. At present, there is no packaging cell line able to carry out these functions. Standard production methods are based on the co-infection of HC-Ad and a helper adenovirus (HV) that provides all viral proteins in trans. Both HC-Ad and HV genomes replicate inside the packaging cells, but encapsidation of the HV is selectively blocked. This is obtained by flanking C with recognition sequences for recombinases constitutively expressed by the cells, such as FLP 5 or Cre. [6] [7] [8] In particular, methods based in the Cre-loxP system have been recently optimized and are being considered for clinical application. 9, 10 However, some HV genomes escape this cleavage, are encapsidated and contaminate the final preparations of HC-Ad. The extent of contamination varies between different methods and laboratories, 7, 11 ranging between 0.01 and 1%, but these data are difficult to compare because of the lack of a standardized method for quantification of HC-Ad. In addition, high levels of HV accumulation can interfere with the packaging of HC-Ad during the amplification process, resulting in very low yields of vectors. One of the weak points of the protocol is the need of sustained expression of the recombinase during the amplification process. Comparing different packaging cells, the intensity of Cre expression correlated with their ability to cleave C, and this contributed to the improvement of HC-Ad production. 12 However, it has been described that the expression of Cre recombinase in the packaging cells decreases in late stages of vector co-amplification as a result of the shut-off of cellular protein synthesis produced by the HV. 13 This is the moment when the function of the Cre recombinase should be most intense in order to cleave C in an increasing number of HV genome copies. Therefore, it would be desirable to express the recombinase in the context of the HV genome. This should obtain a parallel increase in the HV copies and the amount of enzyme that inactivates their encapsidation. This approach faces the challenge of producing a vector expressing a recombinase that can block its own genome packaging. In the present work, we describe a self-inactivating adenovirus (AdTetCre) based on this principle, and evaluate its performance as HV for the production of HC-Ad. Complementary mechanisms to regulate the function of a virally encoded Cre recombinase version allowed the production and amplification of AdTetCre. Tight control of Cre expression was obtained by an optimized tet-on inducible system. 14 In addition, the use of a previously described chimeric version of Cre (MerCreMer), 15 allows an independent level of control. MerCreMer is a fusion protein displaying hormone-binding domains from a mutated estrogen receptor at both ends of the recombinase. In the basal state, MerCreMer is sequestered in the cytoplasm, and the addition of 4-hydroxytamoxifen (TAM) causes translocation to the nucleus, where it can mediate the excision of floxed sequences. We provide evidence that production of AdTetCre can be efficiently restricted by treatment with doxycycline (DOX) plus TAM, and that the virus can be used as HV for the production different HC-Ads with high yield and purity.
RESULTS

Construction of AdTetCre
Our objective was to obtain an adenoviral vector expressing a recombinase that will be able to cleave its own C in an inducible fashion. To this end, we flanked the packaging signal of an E1/E3 deleted adenovirus with loxP sites, and incorporated a drug-inducible system to control the expression of a chimeric Cre-recombinase protein (MerCreMer). 15 The inducible system is based on the optimized rtTA2(s)-M2 transactivator 14 expressed under the control of a constitutive phosphoglycerate kinase promoter (Figure 1a ). In the presence of the tetracycline analog DOX, rtTA-M2 changes conformation and activates the tet-O containing promoter that controls expression of MerCreMer. This fusion protein offers an additional, posttranslational level of control based on TAM-induced translocation to the nucleus. To further restrict expression of MerCreMer during the process of AdTetCre amplification, we generated a packaging cell line stably expressing the transcriptional repressor tTS (293tTS). These cells were used for the rescue of the AdTetCre virus using homologous recombination, as described in the Materials and methods section. Further work demonstrated that expression of tTS is not required for the production of AdTetCre, and the virus can be routinely amplified in HEK293 cells. Compared with a standard first-generation adenoviral vector, the growth of AdTetCre is only slightly retarded, but there is not a difference between HEK293 and 293tTS cells, as long as TAM and DOX are not added to the culture medium ( Supplementary  Figure 1) . Electron microscopy analysis of purified AdTetCre confirmed the normal morphology of virions, with o10% of empty capsids (Supplementary Figure 2a) . To verify the function of the inducible system in the context of the viral genome, we infected HEK293 cells with AdTetCre in the presence or absence of TAM and DOX and analyzed MerCreMer expression by western blot. As shown in Figure 1b , MerCreMer is undetectable in the basal state, but it is produced in response to DOX. Surprisingly, TAM cooperated with DOX in the stimulation of MerCreMer expression. These results suggest that the presence and activity of the recombinase can be tightly controlled. In 293Cre4 cells infected with AdTetCre, the expression of virally encoded MerCreMer was more abundant than the constitutive Cre (Figure 1c) , and it was not affected by the shutoff of cellular protein synthesis caused by adenoviral infection (Figure 1c) .
However, strong accumulation of MerCreMer was only observed 24 h after infection with the AdTetCre virus. This delay is inherent to the function of the inducible system, which requires previous production of the transactivator.
The production of AdTetCre is inhibited by TAM and DOX treatment Next, we investigated if the AdTetCre virus can be self-inactivated by controlled expression of the virally encoded recombinase. Cells were pretreated or not with DOX and TAM, and then were infected with AdTetCre. Cell lysates were collected 48 h later to analyze cleavage of C in the viral genome and to quantify viral production. PCR analysis of DNA extracted from the cells indicates that a fraction of AdTetCre genomes are devoid of C in the basal state, both in 293tTS and HEK293 cells, but the addition of DOX and TAM causes a stronger, virtually complete excision of this sequence in HEK293 cells ( Figure 2a) . As a consequence, treatment with this combination of drugs caused a drastic reduction in the production of infective viral particles (vps) (Figure 2b ). Individual treatment with DOX and TAM reduced the titers of AdTetCre in HEK293, but not in 293tTS. However, in the absence of treatment the viral burst was undistinguishable in both cell lines, which is in agreement with the ability of 293 cells to support efficient production of AdTetCre. The blockade of virus production was not due to a nonspecific effect of DOX and TAM, since a first-generation adenoviral vector (Ad-CMV-LacZ) was not affected (Supplementary Figure 3) . Next, we compared the behavior of AdTetCre in HEK293 and 293Cre4 cells. As expected, the virus was sensitive to the endogenous Cre constitutively expressed in 293Cre4 cells, and simultaneous activation of MerCreMer by DOX and TAM treatment achieved the best inhibition of virus production ( Figure 2c ). This inhibition was not due to a reduction in the replication of viral genomes (Figure 2d ), pointing to blockade of encapsidation as the most likely mechanism.
AdTetCre can be used as HV for the production of high-quality HC-Ad stocks The results described above suggest that AdTetCre in combination with the 293Cre4 packaging cells ensures reliable and maintained expression of the recombinase, and this achieves efficient abrogation of viral packaging. Therefore, we tested the performance of AdTetCre as helper in the production of different HC-Ads. The process started with transfection of 293Cre4 cells with the genome of the HC-Ad and further infection with AdTetCre, in the presence or absence of DOX and TAM, as indicated. Cellular lysates were obtained 48 h later, and used in conjunction with fresh AdTetCre in subsequent rounds of amplification, as described in Materials and methods section. To facilitate the quantification of the vector, we constructed a HC-Ad carrying the enhanced green fluorescent protein (HCA-EGFP). Infective particles generated in each step were determined in cell lysates by infection of permissive HEK293 cells. Fluorescence detection and immunocytochemistry of late viral proteins were used to distinguish cells infected with HCA-EGFP and AdTetCre, respectively. As expected, if expression of MerCreMer was not activated with TAM and DOX treatment, the function of AdTetCre was similar to a standard HV (AdLC8cluc) 6 in which C is flanked by loxP sites, but there is no expression cassette for the recombinase (Figures 3a and b) . In contrast, in 293Cre4 cells treated with DOX and TAM, HV contamination was reduced significantly (0.01 versus 1.64%), and AdTetCre remained several orders of magnitude lower than HCA-EGFP during all the process (Figure 3c ). We observed the same tendency when a different HC-Ad expressing the LacZ gene (KCZ) was amplified under the same conditions ( Figure 3d ). Although further purification steps contribute to the elimination of HV particles in the final preparations of HC-Ad, these results suggest that AdTetCre contributes to reduce the accumulation of HV from early steps in the process. Interestingly, the efficient restriction of AdTetCre production observed in 293Cre4 cells was partially lost when the process was performed in HEK293 cells (Figure 3e ), suggesting that the endogenous Cre is needed to maintain the recombinase activity in the early times post-infection, until virally encoded MerCreMer accumulates.
The ability of AdTetCre to support preferential amplification of HC-Ad versus HV has been demonstrated with vectors from diverse origins, indicating that the method can be applied for the amplification of HC-Ad with different transgenes and stuffer DNAs. In Table 1 , we summarize the yield and purity obtained with several laboratoryscale preparations of HC-Ad carrying reporter or therapeutic genes. Production of 410 12 vp were routinely obtained, which accounts for an average of 9.4Â10 3 vp per cell in these conditions. The integrity of vector particles was verified by electron microscopy (Supplementary Figure 2b) . Presence of infective HV particles can be readily determined by titration in 293 cells. In the case of HC-Ad-expressing EGFP or LacZ reporter genes, direct quantification of infective, transducingcompetent particles is possible by fluorescence detection and X-gal staining, respectively. A more general method based on detection of infective vector genomes is also available. 16 These procedures allow functional determination of helper contamination (expressed as Self-inactivating helper adenovirus M Gonzalez-Aparicio et al percentage of infective unit (iu) HV versus iu HC-Ad), which ranged from 1.7 to 0.0002%. In the last column of the table, we include the percentage of HV iu over the total amount of vp, which is another parameter commonly used to estimate HV contamination. 1 Importantly, HC-Ads stocks produced from the original transfection can be used for a single step amplification process (re-infection protocol) with a considerable gain of time and virus yield, without compromising the quality of the vectors (Table 1) . This would also reduce the amount of cells and tissue culture dishes needed.
AdTetCre is functional in a wide range of multiplicity of infections (MOIs) Production of HC-Ads requires a delicate balance between the relative amounts of packaging cells, HV and HC-Ad. This should be empirically determined and maintained in the course of the amplification process. 17 To investigate if AdTetCre confers more flexibility to the system, we carried out amplification of the HC-EGFP vector using increasing amounts of AdTetCre or AdLC8cluc as HV. As shown in Figure 4 , contamination with AdTetCre remained low (below 0.1%) when used at MOIs up to 25. In contrast, slight increases in the MOI of AdLC8cluc caused a sharp elevation of HV accumulation, suggesting that the capacity of 293Cre4 cells to block encapsidation of this AdLC8cluc had been easily saturated. In terms of vector production, high MOIs of either AdTetCre or AdLC8cluc were not always associated with increased yields of HC-Ad (Figure 4b ).
Residual AdTetCre contaminants are highly attenuated Although encapsidation of AdTetCre can be efficiently blocked, a small amount of this HV is still present in the final preparations. To determine if this viral escape is due to inefficient cleavage of C, we analyzed the presence of this sequence in the genomes of AdTetCre virus that contaminate a stock of the vector KCZ. PCR amplification of the region corresponding to the left end of AdTetCre failed to detect fragments with the full size, consistent with complete cleavage of C (Figure 5a ). DNA sequencing confirmed the absence of this region, with the expected Cre-mediated excision that leaves only one of the two loxP sites. In addition, Southern blot analysis of this sample using a specific probe only detected the C corresponding to KCZ (Figure 5b ). This rules out the possibility that genetic recombinations have resulted in re-localization of this sequence elsewhere in the AdTetCre genome. These results suggest that residual AdTetCre contaminants have been encapsidated in the absence of a canonical C, and raise questions about the functionality of these particles. To address this point, we infected HEK293 cells with an aliquot of the KCZ stock so that the MOI of AdTetCre reached 10. Other cells were infected with the same MOI of the purified AdTetCre virus produced in permissive conditions (no restrictions for packaging). We analyzed the amplification of the virus 48 h later, in the presence or absence of DOX and TAM. The contaminant AdTetCre was severely impaired in its capacity to generate a new viral progeny, compared with the original virus (Figure 5c ). Moreover, the few vps produced were insensitive to inactivation with DOX and TAM, and showed a reduced efficacy for transgene expression (Figure 5d ), which is compatible with the loss of C and the attenuation of the virus. In contrast, when the same experiment was performed using a KCZ stock produced with AdLC8cluc as HV, the contaminants retained the activity of the original virus, and viral production was reduced in 293Cre4 cells compared with HEK293 cells (Figure 5c, right panel) . The fact that 
Self-inactivating helper adenovirus M Gonzalez-Aparicio et al
AdLC8cluc contaminants are fully infective and sensitive to Cre suggests that in this case, the contamination is due to incomplete cleavage of C.
HC-Ad vectors amplified with the aid of AdTetCre sustain long-term expression in vivo
To verify the quality of vectors prepared following this new method, we studied their ability to support long-term expression of transgenes in vivo. We used the HC-Ad/RUmIL-12 virus, which encodes the murine interleukin-12 (IL-12) under the control of a mifepristoneinducible system. 18 This is a stringent test, as IL-12 exerts potent immunostimulatory functions 19 that could reduce the persistence of the vector. HC-Ad/RUmIL-12 was administered intravenously to C57BL/6 mice, and IL-12 expression was induced by intraperitoneal injection of mifepristone at the indicated times. Quantification of IL-12 in the serum of animals demonstrated a remarkable stability of transgene expression for at least 1 year (Figure 6a) , with a slow decay compatible with the non-integrative nature of the vector. In fact, the reduction of IL-12 production observed at late time points correlated with a decrease in the vector copy numbers quantified in the liver of animals ( Figure 6b ).
DISCUSSION
Development of reliable methods to produce HC-Ad would facilitate the use of these vectors in basic and applied research, and it is a requisite for their implementation in the clinical setting. Our results indicate that a virally encoded recombinase cooperates with Cre expressed in packaging cells to ensure efficient cleavage of C in the HV. One of the major obstacles in the development of the selfinactivating HV described here was to ensure the viability of such a vector. Plasmids containing the coding sequence of Cre together with loxP sites are highly unstable even in Escherichia coli (E. coli) (data not shown). The insertion of an intron in the coding sequence of the recombinase could avoid the production of a functional protein in the bacteria. 20 In our case, we could circumvent this problem by assembling the AdTetCre genome through homologous recombination of separate plasmids in 293tTS cells, where the multi-layer mechanism of control described here is fully functional. Cleavage of C was not completely avoided, but still the production of AdTetCre does not differ from other first-generation adenoviral vectors, the structure of the virions is normal and the virus retains enough activity to work as a HV at relatively low MOIs. The possibility of controlling the cleavage of C by treatment with DOX and TAM offers the opportunity to study basic aspects of adenovirus assembly. In particular, the structure of particles generated when excision takes place at different times in the viral cycle would be very informative. Although these studies are beyond the scope of this study, we have performed a functional characterization of the residual AdTetCre particles that contaminate the stocks of HC-Ad. Interestingly, infective particles can be detected, but PCR and Southern blot analysis revealed that virtually all of them are devoid of C. Encapsidation of viral genomes in the absence of all the core elements that integrate the packaging signal is a very inefficient event 21, 22 that probably requires the forced conditions established here, and generates inactive particles. 23 Alternatively, viral genomes can attach to the capsids and become internalized in cells without being really encapsidated. 24 This suggests that further reduction of HV contamination, if necessary, would require additional mechanisms different from the selective cleavage of C. Other methods based on delayed HV encapsidation 11 or genome size restrictions 25 can be complemented with the strategy described here. An advantage of AdTetCre over standard HVs is the fact that the residual contaminants are highly attenuated, in terms of virus replication and expression of the transgene. This is an important consideration, because expression of the recombinase by AdTetCre could rise safety concerns in humans if a significant number of cells were transduced. Different mechanisms contribute to avoid this possibility, including the inducible system and the structure of the MerCreMer fusion protein. In addition, loss of the expression cassette was observed in some escape variants of AdTetCre maintained under DOX and TAM pressure (not shown). Overall, these findings indicate that the mechanisms that contribute to the persistence AdTetCre particles are associated with a drastic reduction in their biological activity. On the other hand, the reduction of HV contamination achieved by AdTetCre should decrease the side effects associated with the immune response against these vectors. Initial versions of HV based on E1/E3 deleted backbones showed a tendency to recombine with E1 sequences present in the packaging cells to produce replication competent Ad. 6 The problem was solved in the AdLC8cluc HV by inclusion of additional sequences in E3 to increase the size of the genome, so a potential transfer of E1 sequences would render a genome too large to be packaged. 6 In the case of AdTetCre, the incorporation of the sequences encoding the inducible system for MerCreMer expression (5.5 kb) increases the size of the genome to nearly 35.3 kb, very similar to AdLC8cluc. In fact, we did not detect (n¼5) were killed 22 and 433 days after vector administration (early and late time points, respectively), and vector copy numbers were determined by quantitative PCR. **Po0.01.
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accumulation of replication competent Ad in the HC-Ad stocks produced with AdTetCre when they were analyzed by quantitative PCR for the E1 region in HeLa cells, and no cytopathic effect was observed (not shown). In addition, the risk of generating replication competent Ads can be minimized by using PER.C6 as packaging cells. 26 Another potential problem comes from recombination between C in HV and HC-Ad, which would result in the loss of one of the loxP sites in the HV. This can be avoided by changing the orientation of C or decreasing the homology of both sequences.
In the present form, our method requires endogenous expression of Cre in packaging cells for optimum performance. We believe this is due to the fact that accumulation of virally encoded MerCreMer at high levels takes 24 h because of the function of the inducible system. In essence, 293Cre4 and AdTetCre complement each other because their kinetics of Cre expression overlap and ensure maintenance of the recombinase activity during the amplification process. Therefore, we could expect that the system based on AdTetCre may be more efficient in packaging cells with high expression of Cre, such as the 116 cell line. In this case, the difference between AdTetCre and a standard HV could be reduced.
AdTetCre is fully compatible with the current manufacturing protocols for HC-Ad, 7 and makes these techniques more robust and reproducible. In addition, the system can be re-designed for the expression of other recombinases apart from Cre. 5, 27 As the majority of the recombinase is expressed by AdTetCre at the time of virus assembly, it is spontaneously adapted to the abundance of HV copies in the course of virus amplification. Therefore, the new system is more flexible in terms of the amount of HV tolerated without resulting in unacceptable contamination, with the limit imposed by the encapsidation of C-free genomes, as mentioned previously. This alleviates the need to find the exact proportion of packaging cells, HC-Ad and HV that allows preferential amplification of the HC-Ad in each step of the process. We believe this will facilitate the implementation of the method in different laboratories, and the adaptation to large-scale production. We have focused in the reduction of HV contamination during the process of amplification, and our present results are already in line with the best available protocols that are being considered for clinical applications. But further improvement in the quality of HC-Ad stocks can be obtained by advanced purification steps based on density gradients or other techniques, 28 with optimized combinations of HC-Ad and HV backbones to facilitate separation. This will also contribute to improve the vp/iu ratio in the final preparations. We believe that expression of the transgenes from the vectors may have an influence on the amplification process. Constitutive, intense expression of EGFP or b-galactosidase may interfere with the viral cycle and the expression of cell-derived recombinase. In contrast, vectors with tissue-specific expression of transgenes such as HC-Ad/RUmIL-12 could be easier to amplify. Although more experience is needed to confirm this hypothesis, our data suggest that limitation of transgene expression in packaging cells may facilitate the production of HC-Ad.
In summary, we describe here a self-inactivating adenovirus that can be used as HV for the production of high-quality HC-Ad with potential application in humans.
MATERIALS AND METHODS
Cell lines and first-generation adenoviruses
The packaging cell line 293tTS is a clone derived from HEK293 (ATCC#CRL-1573, ATCC, Rockville, MD, USA). It was established by co-transfection of the plasmids pTet-EF1a-tTS and pCDNA3.1 (Invitrogen, Carlsbad, CA, USA), and selection with 400 mg ml -1 G418 (GIBCO, Gaithersburg, MD, USA). The pTetEF1a-tTS plasmid was derived from pTet-tTS (Clontech, Mountain View, CA, USA), by substitution of the cytomegalovirus (CMV) promoter with the EF1a promoter. The cell line 293Cre4 (ref. 29 ) is a courtesy of Dr Stefan Kochanek, University of Ulm, Germany. All cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 2 mM L-glutamine. G418 (400 mg ml -1 ) was added to the medium of 293Cre4 and 293tTS cells. All cells were maintained at 37 1C with 5% CO 2 in a humidified incubator. AdLC8cluc is a standard HV 6 (courtesy of Dr Stefan Kochanek). Ad-CMV-LacZ is a first-generation adenovirus carrying the b-galactosidase gene under the control of the CMV promoter. 30 Both viruses were amplified in HEK293 cells and purified by ultracentrifugation in CsCl gradients, as described below.
Construction of AdTetCre
This is an E1/E3 deleted adenovirus with loxP sites flanking its C, and carrying an inducible expression system for the recombinase MerCreMer in the E1 region. Details about the construction are available on request. Viral sequences were derived from the pAdEasy1 plasmid. 31 To obtain the inducible system, the transactivator rtTA2S-M2 was placed under the control of the phoshphglycerate kinase promoter in the plasmid pGKrtTA. The MerCreMer recombinase from the plasmid pANMerCreMer 15 (courtesy of Dr M Reth, Max-Planck Institute of Immunobiology, Germany) was subcloned into HindIII-XbaI sites of the plasmid pO 7 Pal-luc to obtain the palbMerCreMer plasmid. Both transcription units were incorporated in a single plasmid (prtTAMerCre) by subcloning the XhoI-SalI fragment of palbMerCreMer into pGKrtTA. However, introduction of the entire cassette into the adenoviral backbone containing loxP sites caused cleavage of C in the plasmid, probably because the mechanisms that restrict recombinase function are not functional in E. coli. To overcome this problem, we constructed two independent plasmids (pAdLoxPMerCre and pShutMer) with overlapping sequences that reconstitute the AdTetCre genome by homologous recombination in the packaging cells. On co-transfection of the linear plasmids in 293tTS cells, cytopathic effect was observed and the genomic structure of the resulting virus was confirmed by DNA sequencing. The size of the AdTetCre genome is 35.3 kb.
Production of HC-Ads
The genome of the HCA-EGFP vector was obtained as follows. The EGFP gene flanked by XbaI and NotI sites was subcloned into the NheI and NotI sites of the plasmid pIRES (Clontech), to obtain the pCMV-EGFP plasmid. A BglII-NaeI fragment containing the CMV promoter, the EGFP gene and the SV40 poly A signal was blunt end-ligated into the shuttle plasmid pLPBL1-Zeo (courtesy of Dr Brendan Lee, Baylor College of Medicine, Houston, TX, USA) to obtain the pL-EGFP plasmid. The entire expression cassette was then liberated by AscI digestion and introduced into the AscI site of the plasmid pDelta28E4 (ref. 32) (courtesy of Dr Brendan Lee) to obtain the pHCA-EGFP plasmid. The length of the HC-Ad genome is 30.4 kb. The pRS25 plasmid contains the genome of HC-Ad/RUmIL-12, a HC-Ad vector carrying a liver-specific inducible system for the expression of murine IL-12, as previously described. 18 The pKCZ (courtesy of Dr Stefan Kochanek) contains the sequence of a HC-Ad vector expressing the b-Galactosidase (LacZ) gene under the control of a CMV promoter. The pHCA-EGFP, pRS25 and pKCZ plasmids were digested with PmeI to liberate the vector genome, ethanol-precipitated and resuspended in Tris 10 mM, pH 8 at a concentration of 1 mg ml -1 . For rescue of HC-Ad vectors (step 0, P0), 293Cre4 cells are seeded in 60 mm culture plates (10 6 cells per plate), pretreated for 24 h with 0.8 mM TAM and 1 mgr ml -1 DOX, and transfected with 15 mg of the corresponding plasmids, using lipofectamine 2000 (Invitrogen). After 6 h, cells are infected with AdTetCre at a MOI of 1 iu per cell in the presence of DOX and TAM. After 48 h, cells are collected, resuspended in 0.2 ml of Tris 10 mM pH 8.1 and lysed by three rounds of freezing and thawing. Lysates are centrifuged at 2500 revolutions per minute (r.p.m.) for 5 min, and 150 ml of the supernatant is used for subsequent steps (S) of amplification in combination with AdTetCre infection at MOI 1 in DOX and TAM-treated cells. S1 to S3 are performed in 60 mm plates. In S4, 150 ml of lysate from S3 is used to infect two 150 mm plates containing 10 7 cells. In S5, 50% of lysate from S4 is used to infect 10 150 mm plates, or 100% of the lysate is used to infect 20 plates. In S6, 100% of lysate from S5 is used to infect 60 150 mm plates. In all cases, the MOI of AdTetCre is maintained at 1. Instead of starting from the transfection of the HC-Ad genome, some batches were Self-inactivating helper adenovirus M Gonzalez-Aparicio et al produced following a 're-infection protocol'. Briefly, this protocol is based on the direct co-infection of a large amount of packaging cells with AdTetCre at MOI 1, together with the purified HC-Ad to be amplified, at 1.000 vp per cell. In all cases, viruses are purified after the last amplification step using two consecutive CsCl density gradients. The first, discontinuous gradient consists of three CsCl phases with a density of 1.5, 1.35 and 1.25 mg ml -1 . Lysates from the last step of amplification are centrifuged at 3400 r.p.m. for 20 min and loaded on top of the 1.25 mg ml -1 CsCl phase. After centrifugation at 25 000 r.p.m. in a SW32Ti rotor (Beckman, Brea, CA, USA), the band in the interphase of 1.25 and 1.35 densities is collected and loaded on top of a 1.35 mg ml -1 CsCl solution. After centrifugation at 30 000 r.p.m. in a SW40Ti rotor (Beckman), the lower band is collected and desalted using a Sephadex G-50 (Sigma, St Louis, MO, USA) size exclusion column. Virus is eluted in Tris 100 mM pH 8.1, and fractions containing the highest OD 260 are combined. After adding glycerol (10% v/v), stocks of viruses are kept at À80 1C.
Quantification of viruses and viral genomes
For quantification of vps, samples were treated with 10% sodium dodecyl sulfate (SDS) for 10 min and the absorbance at 260 nm was measured in a spectophotometer, as previously described. 33 Quantification of iu of HVs and the first-generation adenovirus Ad-CMV-LacZ was done using the Adeno-X rapid titer kit (Clontech), and verified by end-limiting dilution cytopathic assay 34 in permissive cells (HEK293 or 293tTS). In the case of HC-Adexpressing reporter genes (EGFP and LacZ), viral titers were determined by infection of HEK293 cells with serial dilutions of the vectors and quantification of infected cells by fluorescence detection and X-gal reaction, respectively, as described elsewhere. 35 In these cases, the term iu actually refers to transducing units. 5 In the case of HC-Ad/RUmIL-12, quantification of iu was performed by PCR, as recently described. 16 For quantification of HV genomes, DNA was extracted from cell lysates using the High Pure Viral Nucleic Acid Kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. A quantitative PCR was performed using primers specific for the E4 region: 5¢-A AACTGGTCACCGTGATTAAAAAG-3¢ (forward) and 5¢-CGATCATTAATT AACATCATCAATAATATACC-3¢ (reverse). For quantification of HC-Ad/ RUmIL-12 vector genomes in the liver of mice, DNA was extracted using the QIAamp DNA Mini Kit (250) (Qiagen, Düsseldorf, Germany) according to the manufacturer's instructions. Primers specific for the IRES region were used: 5¢-GCCCGTCTTTTGGCAATGTG-3¢ (forward) and 5¢-CCCCTAGGAATGCTC GTCAA-3¢ (reverse). PCR reactions were performed in a Bio-Rad iQ iCycler Detection System (Bio-Rad Laboratories, Ltd, Hercules, CA, USA) with SYBR green fluorophore sample. To calculate the amount of copies present in each sample, a standard curve was prepared.
Southern blot
Viral DNA was isolated from, 10 9 vp of purified virus by 30-min treatment with 1% SDS and 100 mg ml -1 proteinase K (Roche) at 37 1C. After phenol extraction, viral DNA was precipitated with ethanol, resuspended in water and digested with HindIII. In the case of the plasmid control (pKCZ), digestion was performed with HindIII and PmeI. Samples were run in an agarose gel and transferred to a Hybond-N+ membrane (Amersham, Uppsala, Sweden). Probes for specific for C were prepared by PCR amplification from wild-type adenovirus 5 DNA with the following set of primers: 5¢-TTTTAGGCGGAT GTTGTAG-3¢ (forward) and 5¢-TTACGCGCTATGAGTAACAC-3¢ (reverse). Probes were labeled with [ 32 P]dCTP with a random-primed DNA Labeling Kit (Roche). Prehybridization was performed at 60 1C for 2 h in 5 mM EDTA, 0.75 M NaCl 2 , 0.5% SDS, 50 mM Tris and 200 mg ml -1 tRNA and the membrane was then hybridized overnight at 60 1C. After washing with 2Â SSC and 0.1% SDS at 60 1C, radioactive signal was visualized by autoradiography (Hyperfilm; Kodak, Madrid, Spain) and phosphorimager analysis (Cyclone; Perkin-Elmer, Boston, MA, USA).
Immunoblotting
Cells were harvested in TNE buffer (50 mM Tris pH 7.5, 5 mM EDTA and 100 mM NaCl) supplemented with 1% Igepal and a cocktail of protease inhibitors (Complete Tablets, Roche). After sonication, 20 mg of protein were separated on a 8% SDS-polyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane (Whatman, Scleicher and Schuell, St Louis, MO, USA). Detection was performed by incubation with 1:10 000 anti-Cre monoclonal (Novagen, Madison, WI, USA) or 1:1000 anti-b-galactosidase (Sigma) primary antibodies. Peroxidase-conjugated secondary antibodies were 1:5000 goat anti-rabbit immunoglobulin G (Bio-Rad) and 1:5000 anti-mouse immunoglobulin G (Pierce, Rockford, IL, USA). Detection was performed by Western Lighting chemiluminescence reagent (Perkin-Elmer Life Sciences). Homogeneous sample loading was verified with an anti-glyceraldehyde 3-phosphate dehydrogenase antibody (AbD Serotec, Düsseldorf, Germany) at 1:5000 dilution. Owing to differences in the intensity of expression between Cre and MerCreMer, when they were analyzed in the same samples the membrane containing the transferred proteins was divided before detection to allow optimization of exposure times.
Animal and treatment procedures
The HC-Ad/RUmIL-12 vector (3Â10 10 vp per mouse) was intravenously administered to 7 weeks old female C57BL/6 mice. Induction of IL-12 expression was carried out by intraperitoneal injection of 250 mg kg -1 mifepristone (RU486, Sigma) dissolved in a total volume of 70 ml sesame oil as previously described. 18 Blood was collected 10 h after each induction, and the concentration of IL-12 in serum was quantified by an OptEIA mouse enzymelinked immunosorbent assay kit (BD Biosciences, San Diego, CA, USA). Animals were maintained under specific pathogen-free conditions and all procedures were carried out following protocols approved by the local ethical committee in accordance with recommendations for proper care and use of laboratory animals.
Electron microscopy
Purified virus samples were adsorbed to glow discharged, collodion/carboncoated copper grids, negatively stained with 2% uranyl acetate, and observed in a JEOL 1011 transmission electron microscope (JEOL, Tokyo, Japan). For empty versus full particle quantification, a double blind experiment was carried out. Code labeled grids were loaded in the electron microscope and fields were selected for image recording at low magnification, solely on the basis of correct staining and sample spreading.
Statistical analysis
Two-tailed unpaired t-test was used to compare two groups of values when n410. For smaller groups, Mann-Whitney non-parametric test was used (GraphPad Prism software, Graphpad Software Inc., La Jolla, CA, USA).
